JPH02286620A - Antihypertensive agent - Google Patents
Antihypertensive agentInfo
- Publication number
- JPH02286620A JPH02286620A JP1108107A JP10810789A JPH02286620A JP H02286620 A JPH02286620 A JP H02286620A JP 1108107 A JP1108107 A JP 1108107A JP 10810789 A JP10810789 A JP 10810789A JP H02286620 A JPH02286620 A JP H02286620A
- Authority
- JP
- Japan
- Prior art keywords
- complex polysaccharide
- extract
- active ingredient
- water
- tea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940030600 antihypertensive agent Drugs 0.000 title abstract 3
- 239000002220 antihypertensive agent Substances 0.000 title abstract 3
- 239000000284 extract Substances 0.000 claims abstract description 28
- 150000004676 glycans Chemical class 0.000 claims abstract description 26
- 239000005017 polysaccharide Substances 0.000 claims abstract description 26
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 26
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 9
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims abstract description 8
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 5
- 239000003524 antilipemic agent Substances 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 14
- 244000269722 Thea sinensis Species 0.000 abstract description 9
- 239000003960 organic solvent Substances 0.000 abstract description 7
- 235000013616 tea Nutrition 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 abstract description 3
- 238000001914 filtration Methods 0.000 abstract description 3
- 231100000053 low toxicity Toxicity 0.000 abstract description 3
- 238000003809 water extraction Methods 0.000 abstract description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract description 2
- LKDRXBCSQODPBY-IANNHFEVSA-N D-sorbose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@H]1O LKDRXBCSQODPBY-IANNHFEVSA-N 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 abstract description 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 2
- 239000006185 dispersion Substances 0.000 abstract 2
- 235000009569 green tea Nutrition 0.000 abstract 2
- 238000002360 preparation method Methods 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000004006 olive oil Substances 0.000 description 5
- 235000008390 olive oil Nutrition 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000385 dialysis solution Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LSHVYAFMTMFKBA-PZJWPPBQSA-N (+)-catechin-3-O-gallate Chemical compound O([C@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-PZJWPPBQSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- CDVZCUKHEYPEQS-BURFZZGCSA-N (2r,3r,4r)-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@@H](O)C=O CDVZCUKHEYPEQS-BURFZZGCSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- LVJJFMLUMNSUFN-UHFFFAOYSA-N gallocatechin gallate Natural products C1=C(O)C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C1OC(=O)C1=CC(O)=C(O)C(O)=C1 LVJJFMLUMNSUFN-UHFFFAOYSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は複合多糖類を有効成分とする抗高脂血症用剤に
関するものである。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to an antihyperlipidemic agent containing a complex polysaccharide as an active ingredient.
（従来の技術）
近年、ウーロン茶に脂質代謝改善作用があることが報告
されており、その活性成分はエビカテキンガレートまた
はエピガロカテキンガレートとされている（特開昭６２
−３０７１１号公報）また本発明者は先に、番茶または
煎茶の水抽出液の有機溶媒処理により、分子量が約４万
であって、Ｌアラビノース（Ｌ −ａｒａｂｉｎｏｓｅ
）Ｄ−リボース（Ｄ −ｒｉｂｏｓｅ） 、 Ｄ−グ
ルコース（ｐ −ｇｌｕｃｏｓｅ ）を主要構成糖とす
る分子量が約４万の複合多糖類の分離、精製に成功し、
該複合多糖類乃至該複合多糖類を含む抽出エキスが、血
糖降下剤、糖尿病予防薬、機能性食品、健康食品として
有用なものであることを見出した（特開昭６３−３０８
００１号公報）。(Prior art) In recent years, it has been reported that oolong tea has a lipid metabolism improving effect, and its active ingredient is said to be shrimp catechin gallate or epigallocatechin gallate (Japanese Patent Laid-open No. 62
In addition, the present inventors have previously discovered that by treating an aqueous extract of bancha or sencha with an organic solvent, L-arabinose having a molecular weight of about 40,000,
) Succeeded in the separation and purification of a complex polysaccharide with a molecular weight of approximately 40,000, whose main constituent sugars are D-ribose (D-ribose) and D-glucose (p-glucose).
It has been found that the complex polysaccharide or the extract containing the complex polysaccharide is useful as a hypoglycemic agent, a diabetes preventive drug, a functional food, and a health food (Japanese Patent Laid-Open No. 63-308
001).
更に、茶菓から有機溶媒による抽出、精製の欠点を解決
し、分子量約４万の複合多糖類を工業的に有効に分離、
精製する方法として限外濾過による方法を確立した（特
願昭６３−１３４６３３号）。Furthermore, we solved the drawbacks of extraction and purification using organic solvents from tea confections, and industrially effectively separated complex polysaccharides with a molecular weight of approximately 40,000.
As a purification method, an ultrafiltration method was established (Japanese Patent Application No. 134633/1983).
（発明が解決しようとする課題）
本発明は、毒性が極めて低く、副作用のない安全性に優
れた抗高脂血症用剤を提供することを課題とする。(Problems to be Solved by the Invention) An object of the present invention is to provide an antihyperlipidemic agent that has extremely low toxicity and is free from side effects and excellent in safety.
（課題を解決するための手段）
前記した複合多糖類は、日常飲用に供されている茶菓か
らの抽出物であるため、毒性が低く、副作用のない極め
て安全性に優れた物質であるが、木発明者は該複合多糖
類について更に研究を重ねた結果、該複合多糖類に脂質
代謝改善作用のあることを確認し本発明を完成するに至
った。(Means for Solving the Problems) The complex polysaccharides described above are extracts from tea confections that are consumed on a daily basis, so they are extremely safe substances with low toxicity and no side effects. As a result of further research on the complex polysaccharide, the inventor of the tree discovered that the complex polysaccharide has a lipid metabolism improving effect, and completed the present invention.
前記特開昭６２−３０７１１号公報に開示された活性成
分は、カテキン等のタンニンであるが、本発明の抗高脂
血症用剤の有効成分は、Ｌ−アラビノース、Ｄ−リボー
ス及びＤ−グルコースを主要構成糖とし、それ以外にＤ
−マン７−ス（Ｄ −ｋｍａｎｎＯ８ｅ ）及びＤ−ソ
ルボース（５ｏｒｂｏｓｅ ）を含む複合多糖類である
。The active ingredients disclosed in JP-A-62-30711 are tannins such as catechin, but the active ingredients of the antihyperlipidemic agent of the present invention are L-arabinose, D-ribose, and D- Glucose is the main constituent sugar, and D
It is a complex polysaccharide containing -man7-ose (D-kmannO8e) and D-sorbose (5orbose).
本発明の複合多糖類は、特開昭６３−３０８００１号公
報に開示された番茶または煎茶の水抽出および水抽出物
の有機溶媒処理により得られる。水抽出は茶菓を０〜８
０℃の水に分散遇
し、約１０分間へ度撹拌し、濾過することにより実施さ
れる。濾液は必要に応じて凍結乾燥して乾燥エキスとさ
れる。乾燥エキスは次いで蒸溜水に懸濁させ、有機溶剤
にて処理される。該有機溶剤による処理は、エチルエー
テル、酢酸エチル、ブタノールで順次処理するのが好ま
しい。カフェインは最初のエチルエーテル処理により除
かれ、またタンニンの一部、その他の不純物は酢酸エチ
ル、ブタノール処理により除かれる。有機溶剤処理後の
水層は、次いで凍結乾燥して乾燥エキスを得る。The complex polysaccharide of the present invention is obtained by water extraction of bancha or sencha and treatment of the water extract with an organic solvent as disclosed in JP-A-63-308001. For water extraction, tea sweets are 0 to 8.
This is carried out by dispersing in water at 0°C, stirring for about 10 minutes, and filtering. The filtrate is freeze-dried to obtain a dry extract, if necessary. The dried extract is then suspended in distilled water and treated with an organic solvent. The treatment with the organic solvent is preferably performed sequentially with ethyl ether, ethyl acetate, and butanol. Caffeine is removed by an initial treatment with ethyl ether, and some tannins and other impurities are removed by treatment with ethyl acetate and butanol. The aqueous layer after organic solvent treatment is then freeze-dried to obtain a dry extract.
この乾燥エキスは本発明の複合多糖類を含有し脂質代謝
改善作用を示すことから、抗高脂血症用剤として製剤化
することができる。Since this dried extract contains the complex polysaccharide of the present invention and exhibits a lipid metabolism improving effect, it can be formulated as an antihyperlipidemic agent.
次に上記乾燥エキスを水に溶解し、セロファす ンチューブ等を用いて蒸溜水中で透析蓼中、る。Next, dissolve the above dried extract in water and Dialyze in distilled water using a tube, etc.
透析内液の凍結乾燥エキスは、Ｌ−アラビノース、Ｄ−
リボース、Ｄ−グルコース、Ｄ−マンノース、及びＤ−
ソルボースを含んでいる。この乾燥エキスもまた抗高脂
血症用剤として製剤化することができる。The lyophilized extract of the dialysis fluid contains L-arabinose, D-
Ribose, D-glucose, D-mannose, and D-
Contains sorbose. This dried extract can also be formulated as an antihyperlipidemic agent.
更に、上記透析内液乾燥エキスを水に懸濁させ、遠心分
離後上澄液をゲル濾過法により精製することにより純粋
の複合多糖類が得られ、このものも抗高脂血症用剤とし
て製剤化することができる。Furthermore, pure complex polysaccharides can be obtained by suspending the above-mentioned dialysis fluid dry extract in water and purifying the supernatant after centrifugation by gel filtration, which can also be used as an antihyperlipidemic agent. It can be formulated into a formulation.
本発明の複合多糖類は、また特願昭６３−１３４６３３
号に開示された番茶または煎茶の水抽出液の限外濾過に
よる分画により得られる。The complex polysaccharide of the present invention is also disclosed in Japanese Patent Application No. 63-134633.
It is obtained by fractionating an aqueous extract of bancha or sencha by ultrafiltration as disclosed in No.
この方法は、茶菓の水抽出液を、まず分画分子量が５Ｘ
１０’〜１０ Ｘ １０’の限外濾過膜を用いて濾過し
、抽出液中の葉緑素、蛋白質等の分子量が５ Ｘ １０
’〜１０ Ｘ １０’以上の高分子及び繊維状物質など
を除去する０次いで得られた透過液を分画分子量８ Ｘ
１０３〜Ｉ Ｘ １０４の限外濾過膜を用いて濾過を
行う、この処理により、抽出エキス中のカフェイン、タ
ンニン類、その他の低分子物質が限外濾過膜を通して透
過除去されるが同時に溶媒である水も除去されるので抽
出エキスの濃縮が行なわれ複合多糖類の濃縮液かえられ
る。この濃縮エキスは抗高脂血症用剤として製剤化する
ことができるものであるが、これを凍結乾燥した乾燥エ
キスあるいはこの乾燥エキスを水に溶解して透析等の手
段により精製した複合多糖類も、また抗高脂血症用剤と
して製剤化することができる。In this method, the water extract of tea confectionery is first extracted with a molecular weight cut-off of 5X.
Filter using a 10' to 10 x 10' ultrafiltration membrane to ensure that the molecular weight of chlorophyll, protein, etc. in the extract is 5 x 10
0 to remove polymers and fibrous substances with a molecular weight cutoff of 8
Filtration is performed using an ultrafiltration membrane of No. 103 to I Since some water is also removed, the extracted extract is concentrated and the complex polysaccharide concentrate is replaced. This concentrated extract can be formulated as an antihyperlipidemic agent, but it can be prepared as a dry extract obtained by freeze-drying it or as a complex polysaccharide obtained by dissolving this dried extract in water and purifying it by means such as dialysis. It can also be formulated as an antihyperlipidemic agent.
本発明の抗高脂血症用剤は複合多糖類単体または他の有
効成分との混合物或いは製薬学的に許容しうる担体との
組成物の形で使用される。The antihyperlipidemic agent of the present invention is used in the form of a complex polysaccharide alone, a mixture with other active ingredients, or a composition with a pharmaceutically acceptable carrier.
投与方法及び投与剤形としては、散剤、顆粒剤錠剤、カ
プセル剤、内服液、注射剤及び腹腔内投与が可能である
。また複合多糖類は高脂血症予防のための機能性食品及
び健康食品としても利用することができる。The administration methods and dosage forms include powders, granules, capsules, oral solutions, injections, and intraperitoneal administration. Complex polysaccharides can also be used as functional foods and health foods for preventing hyperlipidemia.
（実施例）
む エキス
番茶２０ｋｇを水２８０文に分散し、８０℃で１５分間
攪拌後、濾過し、濾液を減圧濃縮し、８Ｂ４ｉＬとした
。(Example) 20 kg of bancha extract was dispersed in 280 g of water, stirred at 80° C. for 15 minutes, filtered, and the filtrate was concentrated under reduced pressure to make 8B4iL.
この抽出エキスを、まず分両分子量５Ｘ１０’の膜（膜
面積１．０ ｍ’）を用い、１００〜１７０１／ｍ’ｈ
ｒの透過速度で処理し、抽出エキス８６５Ｌを８交び限
外濾過した後、蒸溜水１６文を加え、さらに２文まで限
外濾過を行った。次に、分画分子量１×１０の！ｌＩ！
（膜面積１．０ ｒｒｆ）を用い、３０〜７０見／ゴｈ
ｒの透過速度で透過液１００文を８文まで濃縮し、更に
蒸溜水２３文を加え濃縮をくり返し、分画分子量１〜５
Ｘ １０’の番茶抽出エキス２．５文を得た。This extracted extract was first mixed at 100 to 1701/m'h using a membrane with a molecular weight of 5 x 10' (membrane area 1.0 m').
After processing at a permeation rate of r, 865 L of the extracted extract was ultrafiltered through 8 crosses, 16 liters of distilled water was added, and ultrafiltration was further performed up to 2 liters. Next, the molecular weight cutoff is 1×10! lI!
(membrane area 1.0 rrf), 30 to 70 views/goh
Concentrate 100 grams of permeate to 8 grams at a permeation rate of
2.5 sentences of bancha extract of X 10' were obtained.
オリーブ 怖 ラ トに る５〜６週令のウ
ィスター系雄性ラットに、２０ ｍ ｌ ／ ｋ ｇの
オリーブ油を経口投与することにより、高脂血症ラット
を得る。試料投与群はオリーブ油の経口投与２時間前に
腹腔内（１０（１，４００ｍｇ／ｋｇ）又は経ｏ （１
０００ｍ ｇ／ｋｇ）投与を行った。Hyperlipidemic rats are obtained by orally administering 20 ml/kg of olive oil to 5- to 6-week-old male Wistar rats. The sample administration group received intraperitoneal (10 (1,400 mg/kg)) or oral o (1) 2 hours before oral administration of olive oil.
000 mg/kg) was administered.
採血はオリーブ油の投与４時間後にエーテル麻酔下で心
採血し、血漿中の各脂質濃度を測定した。総コレステロ
ール濃度は ＣｈｏｌｅｓｔｅｒｏｌＣＩＴ −Ｔｅ５
ｔ ＷＡＫＯ，ＨＤＬ−：１１／ステロ一ル濃度はＨ
Ｄ Ｌ −Ｃｈｏｌｅｓｔｅｒｏｌ −Ｔｅ５ｔＷＡＫ
Ｏ，中性脂肪濃度はＴｒｉｇｌｙｃｅｒｉｄｅ Ｇ
−Ｔｅｓｔ ＷＡＫＯを用いて測定した。その結果を
表１に示す。いずれも１群６匹を使用した。Blood was collected from the heart under ether anesthesia 4 hours after the administration of olive oil, and the concentration of each lipid in the plasma was measured. Total cholesterol concentration is CholesterolCIT-Te5
t WAKO, HDL-:11/sterol concentration is H
D L -Cholesterol-Te5tWAK
O, triglyceride concentration is Triglyceride G
- Measured using Test WAKO. The results are shown in Table 1. In each case, 6 animals were used per group.
オリーブ油投与群では、正常ラットに比較して、総コレ
ステロール、中性脂肪濃度は極めて高い値を示したが、
本発明の複合多糖類エキス投与群では、腹腔内投与群、
経口投与群とも総コレステロール、中性脂肪の有意な低
下が認められた。また、ＨＤＬコレステロール濃度は、
オリーブ油投与群では、正常ラット（対照群）に比較し
て減少する傾向を示したのに対して、本発明の複合多糖
類エキス投与群では、腹腔内投与群、経口投与群とも増
加する傾向が認められた。In the olive oil administration group, total cholesterol and triglyceride concentrations were extremely high compared to normal rats;
In the complex polysaccharide extract administration group of the present invention, the intraperitoneal administration group,
A significant decrease in total cholesterol and triglyceride was observed in both oral administration groups. In addition, HDL cholesterol concentration is
The group administered with olive oil showed a tendency to decrease compared to normal rats (control group), whereas the group administered with the complex polysaccharide extract of the present invention showed a tendency to increase in both the intraperitoneal administration group and the oral administration group. Admitted.
オリーブ
単位ｍｇ／＋１
（発明の効果）
本発明の複合多糖類およびそれを含む抽出エキスを有効
成分とする抗高脂血症用剤は高脂血症の治療に有効であ
り、かつ、日常飲用に供されている茶菓からの抽出物で
あるから長期の連用に於ても人体に何等の悪影響も与え
ないものである。Olive unit mg/+1 (Effect of the invention) The antihyperlipidemic agent of the present invention containing the complex polysaccharide and extract containing the same as an active ingredient is effective in the treatment of hyperlipidemia, and is suitable for daily drinking. Since it is an extract from tea confectionery served in Japan, it does not have any adverse effects on the human body even when used over a long period of time.
特許出願人 リードケミカル株式会社（ほか２名）Patent applicant: Lead Chemical Co., Ltd. (and 2 others)
Claims (2)
リボース及びＤ−グルコースを主要構成糖とする複合多
糖類を有効成分とする抗高脂血症用剤。(1) The molecular weight is about 40,000, and L-arabinose D-
An antihyperlipidemic agent containing a complex polysaccharide whose main constituent sugars are ribose and D-glucose as an active ingredient.
れる請求項１記載の複合多糖類を含む抽出エキスを有効
成分とする抗高脂血症用剤。(2) An antihyperlipidemic agent containing as an active ingredient an extract containing the complex polysaccharide according to claim 1 obtained by ultrafiltration of an aqueous extract of bancha or sencha.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1108107A JPH02286620A (en) | 1989-04-27 | 1989-04-27 | Antihypertensive agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1108107A JPH02286620A (en) | 1989-04-27 | 1989-04-27 | Antihypertensive agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH02286620A true JPH02286620A (en) | 1990-11-26 |
Family
ID=14476066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1108107A Pending JPH02286620A (en) | 1989-04-27 | 1989-04-27 | Antihypertensive agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH02286620A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04352726A (en) * | 1990-08-17 | 1992-12-07 | Nikko Kyodo Co Ltd | Arterial sclerosis-preventing agent and functional food having arterial sclerosis-preventing activity |
| WO1999066941A1 (en) * | 1998-06-23 | 1999-12-29 | Ahmad Abdallah Shehadeh | Herbal extract composition and method with immune-boosting capability |
| JP2002080362A (en) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar-dependent gene transcription activator |
| EP1313488A1 (en) * | 2000-07-28 | 2003-05-28 | Bioenergy Inc. | Compositions and methods for improving cardiovascular function |
| WO2004063369A1 (en) | 2003-01-10 | 2004-07-29 | Kagawa University | Gene sequence of l-rhamnose isomerase having new catalytic function and use thereof |
| US7553817B2 (en) | 1999-04-12 | 2009-06-30 | Bioenergy, Inc. | Methods for improving cardiac function |
| US10821123B2 (en) | 2016-02-01 | 2020-11-03 | Bioenergy Life Science, Inc. | Use of ribose for treatment of subjects having congestive heart failure |
-
1989
- 1989-04-27 JP JP1108107A patent/JPH02286620A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04352726A (en) * | 1990-08-17 | 1992-12-07 | Nikko Kyodo Co Ltd | Arterial sclerosis-preventing agent and functional food having arterial sclerosis-preventing activity |
| WO1999066941A1 (en) * | 1998-06-23 | 1999-12-29 | Ahmad Abdallah Shehadeh | Herbal extract composition and method with immune-boosting capability |
| US6030622A (en) * | 1998-06-23 | 2000-02-29 | Shehadeh; Ahmad Abdallah | Herbal extract composition and method with immune-boosting capability |
| US7553817B2 (en) | 1999-04-12 | 2009-06-30 | Bioenergy, Inc. | Methods for improving cardiac function |
| JP2002080362A (en) * | 2000-06-21 | 2002-03-19 | Kao Corp | Ppar-dependent gene transcription activator |
| JP4719372B2 (en) * | 2000-06-21 | 2011-07-06 | 花王株式会社 | PPAR-dependent gene transcription activator |
| EP1313488A4 (en) * | 2000-07-28 | 2005-11-30 | Bioenergy Inc | Compositions and methods for improving cardiovascular function |
| EP1313488A1 (en) * | 2000-07-28 | 2003-05-28 | Bioenergy Inc. | Compositions and methods for improving cardiovascular function |
| US9572882B2 (en) | 2000-07-28 | 2017-02-21 | Ribocor, Inc. | Compositions and methods for improving cardiovascular function |
| WO2004063369A1 (en) | 2003-01-10 | 2004-07-29 | Kagawa University | Gene sequence of l-rhamnose isomerase having new catalytic function and use thereof |
| US7205141B2 (en) | 2003-01-10 | 2007-04-17 | National University Corporation Kagawa University | Gene sequence of L-rhamnose isomerase having new catalytic function and use thereof |
| US7501267B2 (en) | 2003-01-10 | 2009-03-10 | Rare Sugar Production Technical Research Laboratories, Llc | Gene sequence of L-rhamnose isomerase having new catalytic function and use thereof |
| US10821123B2 (en) | 2016-02-01 | 2020-11-03 | Bioenergy Life Science, Inc. | Use of ribose for treatment of subjects having congestive heart failure |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH02111725A (en) | Drug composition | |
| AU644351B2 (en) | Anti-aids viral agent and anticancer action | |
| KR0154984B1 (en) | Extract from leaves of ginko biloba and their processes for preparing ampule containing them | |
| CA2386215C (en) | Method for treatment of chronic venous insufficiencies using an extract of red vine leaves | |
| CN1352563A (en) | Use of phyllanthus for targeted stimulation of the immune system | |
| JPS60214741A (en) | Hypoglycemic agent | |
| JPH02286620A (en) | Antihypertensive agent | |
| JPH0539305A (en) | Immuno suppressive polysaccharide extracted from astragalus membranaceous and pharma- ceutical composition containing same | |
| AU745660B2 (en) | Water-soluble native dry plant extract, especially ginkgo biloba extract with a high terpenoid and flavone glycoside content | |
| JP3130327B2 (en) | Liver dysfunction preventive agent and functional food having hepatic dysfunction preventive action | |
| CN114886914A (en) | Composition for relieving oral ulcer and preparation method and application thereof | |
| EP2182967A1 (en) | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same | |
| KR100893779B1 (en) | The extracting method of Angelica gigas Nakai that has effect of scavenging action on free radical | |
| JPH11228602A (en) | Immune enhancement agent and immune enhancement food | |
| JP3142192B2 (en) | Blood lipid improving agent and composition containing the same | |
| JPH08151329A (en) | Antiviral agent, carcinostatic agent and production thereof | |
| KR0179088B1 (en) | Composition containing rhodiola sachalinesis extract for prophylaxis and treatment of diabetes mellitus | |
| CN109985075B (en) | Ginkgo leaf extract injection and preparation method thereof | |
| JP3183754B2 (en) | Arteriosclerosis inhibitor and composition containing the same | |
| JPH04124139A (en) | Hypoglycemically functioning agent and its production | |
| JP3183758B2 (en) | Blood neutral fat ameliorating agent, method for producing the same, and composition containing the same | |
| KR20060058729A (en) | Neutralizing agent for cavitating toxin | |
| KR0179087B1 (en) | Composition containing rhodiola sachalinesis extract for lowering blood alcohol concentration | |
| US8178135B2 (en) | Aqueous solution of conophylline and/or conophyllidine | |
| JPWO2003035091A1 (en) | Indigo preparation and its use in preventing or treating human immunodeficiency virus infection |